Article Text

PDF
PP 046
POPULATION PHARMACOKINETICS AND DOSING OPTIMIZATION OF TEICOPLANIN IN CHILDREN WITH MALIGNANT HAEMATOLOGICAL DISEASE
  1. Wei Zhao1,
  2. Daolun Zhang2,
  3. Thomas Storme3,
  4. André Baruchel4,
  5. Xavier Declèves5,
  6. Evelyne Jacqz-Aigrain6
  1. 1Department of Clinical Pharmacy, School of Pharmaceutical sciences, Shandong University, Jinan, China; Department of Paediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP, Paris, France; Clinical Investigation Center CIC1426, INSERM, Paris, France; EA7323, Université Paris Diderot-Université Paris Descartes, Press Sorbonne Paris Cité, Paris, France
  2. 2Department of Paediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP, Paris, France
  3. 3Department of Pharmacy, Hôpital Robert Debré, APHP, Paris, France
  4. 4Department of Paediatric Haemato-Oncology, Hôpital Robert Debré, APHP, Paris, France
  5. 5Department of Pharmacokinetics and Pharmacochemistry, Hôpital Cochin, APHP, Paris, France
  6. 6Department of Paediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP, Paris, France; Clinical Investigation Center CIC1426, INSERM, Paris, France; EA7323, Université Paris Diderot-Université Paris Descartes, Press Sorbonne Paris Cité, Paris, France

Abstract

Background Children with haematological malignancy represent an identified subgroup of the paediatric population with specific pharmacokinetic parameters. In these patients, inadequate empirical antibacterial therapy may result in infection-related morbidity and increased mortality, making optimization of the dosing regimen essential. As paediatric data are limited, our aim was to evaluate the population pharmacokinetics of teicoplanin in order to define the appropriate dosing regimen in this high-risk population.

Methods The current dose of teicoplanin was evaluated in children with haematological malignancy. Population pharmacokinetics of teicoplanin was analysed using NONMEM software. The dosing regimen was optimised based on the final model.

Results Eighty-five children (age range: 0.5 to 16.9 years) were included. Therapeutic drug monitoring and opportunistic samples (n=143) were available for analysis. With the current recommended dose of 10 mg/kg/day, 41 children (48%) had sub-therapeutic steady-state trough concentrations (Css,min<10 mg/liter). A two-compartment pharmacokinetic model with first-order elimination was developed. Systematic covariate analysis identified that bodyweight (size) and creatinine clearance significantly influenced teicoplanin clearance. The model was validated internally. Its predictive performance was further confirmed in an external validation. In order to reach the target AUC of 750 mg·h/L, 18 mg/kg was required for infants, 14 mg/kg for children and 12 mg/kg for adolescents. A patient-tailored dose regimen was further developed and reduced variability in AUC and Css,min values compared to the mg/kg-basis dose, making the modelling approach an important tool for dosing individualization.

Conclusions This first population pharmacokinetic study of teicoplanin in children with haematological malignancy provided evidence-based support to individualize teicoplanin therapy in this vulnerable population.

  • ESDP

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.